Paper Details

  1. Home
  2. Paper Details

A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma.

Author: BélandG, ElhilaliM, FradetY, LarocheB, RamseyE W, TewariH D, TrachtenbergJ, VennerP M

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A randomized, double-blind trial comparing nilutamide with placebo in patients with disseminated prostate cancer showed that nilutamide had a positive impact on the objective responses (46% vs 20%, P = 0.001). Progression-free survival was also initially improved in the nilutamide group. Although nilutamide increased median length of survival (from 18.9 to 24.3 months), it did not significantly increase the total survival time.
Paper Details　
Original Abstract of the Article :
A randomized double-blind trial in patients with disseminated, previously untreated prostate cancer (Stage D2) was conducted in eight Canadian centers. All 203 patients enrolled in this study underwent bilateral orchiectomy and were randomized to receive either the nonsteroidal anti-androgen nilutam...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/cncr.1990.66.s5.1074

データ提供：米国国立医学図書館（NLM）

Evaluating Treatment Options for Metastatic Prostate Cancer

This study, conducted in the field of [oncology], investigates the effectiveness of different treatment strategies for metastatic prostate cancer, a challenging disease requiring innovative approaches. The research, using a [randomized controlled trial] design, compares the outcomes of two treatment modalities: castration alone and castration combined with nilutamide, a nonsteroidal antiandrogen.

The authors reveal that the combination treatment, castration plus nilutamide, demonstrates [improved objective response rates] compared to castration alone. While both treatments show similar progression-free survival, the combined treatment might offer [potential benefits] in terms of overall survival. This research offers valuable insights into the treatment landscape for metastatic prostate cancer, potentially guiding clinicians in choosing the most effective treatment approach.

Choosing the Right Treatment for Prostate Cancer

This research indicates that the combination treatment of castration plus nilutamide might offer a more effective approach for managing metastatic prostate cancer. The findings highlight the importance of individualizing treatment strategies based on the patient's specific needs and characteristics.

Navigating the Treatment Landscape for Prostate Cancer

Prostate cancer is a complex disease, and finding the best treatment strategy can be challenging. This study provides valuable information for patients and their healthcare providers in navigating the treatment options available for metastatic prostate cancer.

Dr.Camel's Conclusion

This study, like a camel navigating the shifting sands of cancer treatment, explores the effectiveness of different therapeutic options for metastatic prostate cancer. The findings, like a refreshing oasis, offer valuable insights into the potential benefits of combining castration with nilutamide. This research underscores the importance of personalized approaches in managing this challenging disease, empowering individuals and their healthcare providers to make informed decisions about treatment strategies.

Date :
  1. Date Completed 1990-10-09
  2. Date Revised 2019-06-19
Further Info :

Pubmed ID

2203517

DOI: Digital Object Identifier

10.1002/cncr.1990.66.s5.1074

Related Literature

Article Analysis
・Side Effects of nilutamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.